IgA Nephropathy app study for patients and caregivers
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study uses a mobile app to track how IgA nephropathy (IgAN) affects daily life and what treatments people use. It’s open to patients and their caregivers to help researchers learn more about the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with IgA nephropathy (IgAN), a kidney disease
- You are either an adult with IgAN, or an adult caring for someone with IgAN (adult or child)
- You live in the United States and can read and understand English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding iptacopan to standard care can improve kidney health in adults with IgA nephropathy. You may qualify if you have a kidney biopsy confirming IgA nephropathy and your kidney function is stable enough.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial tests a new drug, HS-10390, to see if it can help people with IgA nephropathy. You may qualify if you have the condition, are on stable blood pressure medication, and meet certain kidney function and lab criteria.
This trial is collecting real-world information from people with IgA nephropathy who are taking the medications iptacopan or atrasentan. The goal is to better understand how these treatments work in everyday medical practice.
This study observes how people with IgA nephropathy respond to standard and newer treatments in everyday medical practice, to understand why some cases are resistant to therapy.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
Hear when a new Immunoglobulin A Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.